RGNX - REGENXBIO Inc.
40.76 +0.29 (0.71%)
After hours: 4:11PM EST
| Previous Close | 41.76 |
| Open | 41.88 |
| Bid | 40.55 x 800 |
| Ask | 42.99 x 900 |
| Day's Range | 40.08 - 42.59 |
| 52 Week Range | 30.38 - 63.21 |
| Volume | 293,179 |
| Avg. Volume | 564,006 |
| Market Cap | 1.5B |
| Beta (3Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings Date | Feb 25, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.67 |
- Simply Wall St.
We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- American City Business Journals
Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Regenxbio Inc Earnings Call
- Investor's Business Daily
The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled
Regenxbio stock toppled below its 50-day moving average early Wednesday after the U.S. Food and Drug Administration put one of the biotech company's gene therapy candidates on hold.
- Zacks
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights
ROCKVILLE, Md. , Nov. 5, 2019 /PRNewswire/ -- Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial ...
- Investor's Business Daily
What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One
Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.
- Investopedia
8 Undervalued Biotech Stocks to Watch Now
As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.
- GlobeNewswire
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery
“Our recent partnerships with REGENXBIO, Bausch Health, and Aura Biosciences demonstrate the broad applicability of our suprachoroidal space injection platform to potentially treat multiple ocular diseases including wet AMD, uveitic macular edema, and choroidal melanoma. With these collaborations and planned internal research and development efforts, we look forward to continuing to expand our pipeline,” said George Lasezkay, Pharm.D., J.D., Chief Executive Officer of Clearside. “Results from multiple preclinical studies support the potential safety and effectiveness of suprachoroidally administered AAV-based gene therapy, and we are excited to advance our partnership with REGENXBIO,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer of Clearside.
- PR Newswire
REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Oct. 29, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Simply Wall St.
Announcing: REGENXBIO (NASDAQ:RGNX) Stock Increased An Energizing 142% In The Last Three Years
REGENXBIO Inc. (NASDAQ:RGNX) shareholders might be concerned after seeing the share price drop 23% in the last...
- Insider Monkey
Is Regenxbio Inc (RGNX) Going to Burn These Hedge Funds?
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
- PR Newswire
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress
ROCKVILLE, Md. , Oct. 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- American City Business Journals
RegenxBio gets positive interim data for eye disease treatment
The prospect of RegenxBio’s product could change the game for the roughly 2 million people who suffer from wet age-related macular degeneration in the U.S., Europe and Japan.
- Zacks
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
- PR Newswire
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
ROCKVILLE, Md., Oct. 11, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). The results were presented by Jeffrey S. Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston and primary investigator for the trial, in a podium presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA.
- Zacks
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
- Benzinga
The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck
Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs. A few FDA approvals came through, with Puma Biotechnology Inc (NASDAQ: ...
- Zacks
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
- Barrons.com
Biotech Roundtable: How to Invest in Medicine’s Future
As medical breakthroughs lead to revolutionary cures, the future looks bright for patients—and patient investors.
- PR Newswire
REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference
ROCKVILLE, Md. , Sept. 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Simply Wall St.
An Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% Undervalued
Does the September share price for REGENXBIO Inc. (NASDAQ:RGNX) reflect what it's really worth? Today, we will...
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
